Frontlight ResearchEarly access
CompletedNo phase
MxA-Guided Antiviral Treatment in Respiratory Viral Infections
Key facts
- Who runs it
- Capital Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 86 people enrolled
- Started
- 12 Dec 2024
- Ended
- 12 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MxA tests
- MxA feedback
- Follow-up at Day 30
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- ≥ 18 years old
- With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapid antigen test or RT-PCR
- Duration of infection ≤14 days for non-severe patients and < 28 days for patients with severe infections
- Currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment
Who cannot take part
- Received interferon therapy within 30 days before screening
- Systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery
- Received vaccine in the past 30 days
- Active tuberculosis
- Co-infected with influenza and COVID-19
- Current endotracheal intubation and mechanical ventilation
- Current vasopressor use
- Known immunosuppression
- With contraindications for antiviral treatment
- Unable to obtain eligible samples
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.
The 2 groups in the trial
- MxA groupTreatment being tested
Perform MxA test; MxA results reported to attending clinicians; Provide MxA-based guidelines on antiviral treatment to attending clinicians; Telephone Visit at Day 30
Treatment: MxA tests, MxA feedback, and Follow-up at Day 30
- Control groupExisting treatment, for comparison
Telephone Visit at Day 30
Treatment: Follow-up at Day 30
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Application of Myxovirus Resistance Protein A in Antiviral Treatment Guidance of Respiratory Viral Infections
- Record updated
- 4 March 2026